Great article – very thorough analysis! I think it’s also interesting to note that Model S and X are effectively the same chassis, further reducing complexity in operations, increasing automation and decreasing overall costs. The direct to consumer model also minimizes channel conflicts, if regulation passes.
The future of medicine.
Valeant is just another predatory pharmaco preying on poor patients.